Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of drug is delivered to the tissue while minimizing downstream particulates. Boston Scientific has more than 20 years of expertise developing and commercializing stents that elute paclitaxel via a polymer across coronary and peripheral vessels. Eluvia’s safety results combined with a holistic review of all Boston Scientific’s long-term clinical data on coronary polymer-based paclitaxel eluting devices showed no difference in all-cause mortality when compared to non-coated devices.
This video was filmed and sponsored by Boston Scientific. It is being distributed in association with Interventional News.
